Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked CD3 T Cell Engagers Utilizing Safebody® Technology - ADAG News | Rallies
Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked CD3 T Cell Engagers Utilizing Safebody® Technology
Adagene Inc. said Third Arc Bio has selected the first lead candidate under an amended strategic collaboration for development of masked CD3 T cell engagers utilizing Safebody® technology.
Adagene said total potential payments to Adagene under the collaboration increased.
ADAG•
